Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

• ClinicalTrials.gov Identifier: NCT00107718
• Recruitment Status: Completed
• First Posted: April 8, 2005
• Last Update Posted: July 27, 2017
• Sponsor: GlaxoSmithKline
• Information provided by (Responsible Party): GlaxoSmithKline

Study Description

Brief Summary:

This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic melanoma.

Condition or disease	Intervention/treatment	Phase
Melanoma	Drug: SB-485232	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 64 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of IL-18 in Melanoma Patients
• Actual Study Start Date: November 15, 2004
• Actual Primary Completion Date: May 19, 2006
• Actual Study Completion Date: May 19, 2006

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

1. Overall response rate of tumor [ Time Frame: Up to 12 months ]
   Tumor response rate (RR) is defined as the percentage of participants achieving either a complete or partial response. Response was at least one measurable lesion as defined by response evaluation criteria for solid tumors (RECIST) criteria or a cutaneous or subcutaneous lesion of at least 1 centimeter (cm) in diameter in one dimension. A distinction was drawn between responses that are confirmed at a repeat assessment and those that are not. If there were unconfirmed responses, then a sensitivity analysis was performed excluding participants with unconfirmed responses. Analysis was performed by both Investigator and independent review committee (IRC). The results were compared and a confirmatory analysis has been presented.

Secondary Outcome Measures :

1. Number of participants with progression free survival [ Time Frame: Up to 12 months ]
   Progression Free Survival is defined as the time from the start of treatment until the first documented sign of disease progression or death due to any cause, whichever occurred first. For participants who did not progress or die, progression free survival was censored at the time of initiation of alternative anti-cancer therapy or time of last contact, whichever occurred first. The times to progression were summarized using the Kaplan-Meier survival curve.
2. Response duration of SB-485232 for tumor treatment [ Time Frame: Up to 12 months ]
   Response duration defined as the date criteria for Complete Response (CR) or Partial Response (PR) (whichever occured first) was first met until the date criteria for recurrent or progressive disease was first met or death due to any cause was reported, whichever occured first. Time to response was defined as the date study drug was first dosed until the date criteria for CR or PR (whichever occured first) was first met.
3. Time to response [ Time Frame: Up to 12 months ]
   Response duration defined as the date criteria for CR or PR (whichever occured first) was first met until the date criteria for recurrent or progressive disease was first met or death due to any cause was reported, whichever occured first. Time to response was defined as the date study drug was first dosed until the date criteria for CR or PR (whichever occured first) was first met.
4. Number of participants with adverse events (AEs), serious adverse events (SAEs), and death. [ Time Frame: Up to 12 months ]
   An AE is any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.
5. Change from Baseline In vital signs [systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature(BT)] [ Time Frame: Baseline (Day 1) to Day 15 and Day 28 of each cycle ]
   Vital signs including SBP, DBP, HR and BT were taken at Day 1 to Day 15 and follow up visits of each cycle. Baseline assessment was performed pre-dose on Cycle 1 Day 1.
6. Number of participants with toxicity grade shift of clinical laboratory parameters over period. [ Time Frame: Baselie (Cycle1,Day 1), Day 2, Day 15 and Follow up (28 days after last dose of Cycle 13) of each cycle ]
   Haematology and Clinical Chemistry together are termed as Clinical Laboratory Parameters.Blood samples were collected at Day 1, Day 2, Day 15 and Follow up of each cycle for assessment of clinical chemistry and haematology parameters. Sodium, Potassium, Chloride, Bicarbonate, Calcium, Glucose, Total protein, Albumin, Lactate dehydrogenase, Uric acid, Phosphorus, Creatinine, Blood urea nitrogen, Total bilirubin, Alkaline phosphatase, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Magnesium were analyzed in clinical chemistry. Similarly, Hemoglobin, Hematocrit, Platelet count, Total white blood cell count, Neutrophil count, Lymphocyte count, Monocyte count, Eosinophil count and Basophil count wee analyzed in haematology. Number of participants with shift of grades from Baseline in hematology and clinical chemistry parameters toxicities have been summarized here.
7. Number of participants with immune response to SB485232 over period. [ Time Frame: Day 15 of each cycle ]
   Immunotherapy for melanoma is based on the premise that the immune system can recognize and attack host tumor cells. This may be achieved by either triggering an immune response or by potentiating an otherwise weak immune response that is capable of recognizing the participant's own tumor. Various dosing schedules and combinations involving IFN-α and interleukin (IL)-2 have been tested. The response rate reported with single agent IL-2, as well as for combinations with Interferon-α, range from a low of 3% (as single agent) to a high of 41% (for the combination), with a small percentage of long term responders. The immune response to SB-485232 was assessed by measuring the anti-SB-485232 levels (total immunoglobulin and immunoglobulin E [IgE]) before starting therapy and at specified time points, throughout the study period.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion criteria:

• Patients must have melanoma that has spread beyond the original location and has not yet been treated.
• Tissue from the spreading melanoma should have been tested to confirm it is melanoma.

Exclusion criteria:

• Patients having hepatitis or HIV infection.
• Taking corticosteroids.
• Patients with the primary site being occular melanoma or patients with melanoma of the brain.

Contacts and Locations

Locations

United States, California

GSK Investigational Site

Los Angeles, California, United States, 90089

GSK Investigational Site

San Francisco, California, United States, 94115

GSK Investigational Site

Santa Monica, California, United States, 90404-2104

United States, Connecticut

GSK Investigational Site

New Haven, Connecticut, United States, 06520

United States, Florida

GSK Investigational Site

Jacksonville, Florida, United States, 32209

GSK Investigational Site

Miami Beach, Florida, United States, 33140

United States, Illinois

GSK Investigational Site

Chicago, Illinois, United States, 60637

United States, Indiana

GSK Investigational Site

Indianapolis, Indiana, United States, 46202

United States, Maryland

GSK Investigational Site

Lutherville-Timonium, Maryland, United States, 21093

United States, New York

GSK Investigational Site

New York, New York, United States, 10016

United States, Ohio

GSK Investigational Site

Toledo, Ohio, United States, 43614-5809

United States, Pennsylvania

GSK Investigational Site

Pittsburgh, Pennsylvania, United States, 15213-2584

Australia, New South Wales

GSK Investigational Site

Waratah, New South Wales, Australia, 2298

GSK Investigational Site

Westmead, New South Wales, Australia, 2145

Australia, Queensland

GSK Investigational Site

Douglas, Queensland, Australia, 4814

GSK Investigational Site

South Brisbane, Queensland, Australia, 4101

GSK Investigational Site

Woolloongabba, Queensland, Australia, 4102

Australia, Tasmania

GSK Investigational Site

Hobart, Tasmania, Australia, 7000

Australia, Victoria

GSK Investigational Site

East Melbourne, Victoria, Australia, 3002

Australia, Western Australia

GSK Investigational Site

Nedlands, Western Australia, Australia, 6009

Sponsors and Collaborators

GlaxoSmithKline

Investigators

• Study Director: GSK Clinical Trials; GlaxoSmithKline

More Information

• Responsible Party: GlaxoSmithKline
• ClinicalTrials.gov Identifier: NCT00107718 History of Changes
• Other Study ID Numbers: SB-485232/006
• First Posted: April 8, 2005
• Last Update Posted: July 27, 2017
• Last Verified: July 2017

Keywords provided by GlaxoSmithKline:

IL-18; treatment naive; Phase 2; melanoma

Additional relevant MeSH terms:

Melanoma; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas